Lilly (Lily) CEO of LLYY.US): We expect the shortage of weight loss drugs to end soon.

David Ricks, CEO of Lilly (LLY.US), said on Thursday that the company's popular weight-loss drug Zepbound would end its shortage in the US in the coming days.

Ricks said the shortage of the injectable GLP-1 product would “quickly” end. “I think it’s possible today or tomorrow,” he said.

Several of Lilly’s and rival Novo Nordisk’s (NVO.US) weight-loss drugs have been in short supply in the US for months, prompting consumers to seek out unregulated combination drugs.

The US Food and Drug Administration (FDA) allows the production of such drugs in short supply to help patients get the necessary treatment, but does not review or regulate those combination drugs as it does traditional prescription drugs.

Hims&Hers Health (HIMS.US), which recently launched a combination drug, fell 13% on Thursday.

Lilly rose 3.5% on Thursday, despite recent pressure on the stock, which has risen 43% this year.